000282538 001__ 282538
000282538 005__ 20251201103218.0
000282538 0247_ $$2doi$$a10.1002/mds.70012
000282538 0247_ $$2ISSN$$a0885-3185
000282538 0247_ $$2ISSN$$a1531-8257
000282538 037__ $$aDZNE-2025-01301
000282538 041__ $$aEnglish
000282538 082__ $$a610
000282538 1001_ $$aHermle, Dominik$$b0
000282538 245__ $$aDigital Outcomes of Upper Limb Ataxia Capture Meaningful Longitudinal Change and Treatment Response
000282538 260__ $$aNew York, NY$$bWiley$$c2025
000282538 3367_ $$2DRIVER$$aarticle
000282538 3367_ $$2DataCite$$aOutput Types/Journal article
000282538 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764580112_18438
000282538 3367_ $$2BibTeX$$aARTICLE
000282538 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282538 3367_ $$00$$2EndNote$$aJournal Article
000282538 520__ $$aBackgroundDigital-motor outcomes promise better responsiveness than clinician-reported outcomes in ataxia trials. However, their patient meaningfulness and sensitivity to change remain to be demonstrated, particularly in the upper limb domain.ObjectivesValidation of quantitative motor (Q-Motor) assessment for upper limb ataxia against patient-reported outcomes and regarding sensitivity to both longitudinal and treatment-induced change, the latter in n-of-1 treatment settings.MethodsSingle-center longitudinal assessment of finger tapping, diadochokinesia, grip-lift, spiral drawing, and target reaching in (1) 36 cross-genotype ataxia patients and 20 controls, validating digital measures for correlations with patient-reported outcome measure (PROM)-ataxia, 2-weeks test–retest reliability, and sensitivity to change within a trial-relevant 1-year follow-up, anchored in Patient Global Impression of Change (PGI-C); and (2) two patients with spinocerebellar ataxia type 27B (SCA27B) on versus off treatment with 4-aminopyridine.ResultsTwenty-four digital measures correlated with the PROM-ataxia upper-limb composite (|ρ| = 0.4–0.7) and had excellent test–retest reliability (ICC = 0.91–0.99). Correlations to individual PROM-ataxia items were specific for functional impairment the respective measure was hypothesized to capture. Speed of finger tapping and diadochokinesia, and smoothness of target reaching (spectral arc length of movement in three dimensions [SPARC3D]) captured 1-year progression in ataxia patients (|rprb| = 0.38–0.51), and specifically in patients with worsening PGI-C. Estimated sample sizes to detect longitudinal change were lower for digital than clinical outcomes (SPARC3D: n = 33, Scale for the Assessment and Rating of Ataxia (SARA): n = 79, nine-hole peg-test: n = 214). Speed of diadochokinesia, stability of grip-lift, and variability of target reaching captured treatment responses to 4-aminopyridine in SCA27B, exceeding minimal detectable and minimal important change.ConclusionDigital upper limb measures capture patient-meaningful 1-year longitudinal and treatment-induced change, and are therefore promising outcomes for upcoming ataxia trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000282538 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282538 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000282538 7001_ $$aSchubert, Robin$$b1
000282538 7001_ $$aBarallon, Pascal$$b2
000282538 7001_ $$0P:(DE-2719)9001643$$aIlg, Winfried$$b3
000282538 7001_ $$aSchüle, Rebecca$$b4
000282538 7001_ $$00000-0002-5904-9517$$aReilmann, Ralf$$b5
000282538 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b6
000282538 7001_ $$0P:(DE-2719)9000792$$aTraschütz, Andreas$$b7$$eLast author
000282538 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.70012$$gVol. 40, no. 11, p. 2486 - 2496$$n11$$p2486 - 2496$$tMovement disorders$$v40$$x0885-3185$$y2025
000282538 8564_ $$uhttps://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.docx
000282538 8564_ $$uhttps://pub.dzne.de/record/282538/files/DZNE-2025-01301.pdf$$yOpenAccess
000282538 8564_ $$uhttps://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.doc
000282538 8564_ $$uhttps://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.odt
000282538 8564_ $$uhttps://pub.dzne.de/record/282538/files/DZNE-2025-01301%20SUP.pdf
000282538 8564_ $$uhttps://pub.dzne.de/record/282538/files/DZNE-2025-01301.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000282538 909CO $$ooai:pub.dzne.de:282538$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000282538 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000282538 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000792$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000282538 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282538 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000282538 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000282538 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-16$$wger
000282538 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000282538 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000282538 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000282538 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000282538 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000282538 980__ $$ajournal
000282538 980__ $$aVDB
000282538 980__ $$aUNRESTRICTED
000282538 980__ $$aI:(DE-2719)1210000
000282538 9801_ $$aFullTexts